de Niet A, Takkenberg R B, Benayed R, Riley-Gillis B, Weegink C J, Zaaijer H L, Koot M, Jansen P L M, Beld M G H M, Lopatin U, Reesink H W
Department of Gastroenterology and Hepatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Scand J Gastroenterol. 2012 Apr;47(4):475-81. doi: 10.3109/00365521.2011.648952. Epub 2012 Jan 23.
In a cohort of 95 chronic hepatitis B patients, who were treated with peg-interferon and adefovir for 1 year, and who had 15% HBsAg loss (overall), no association was found between IL28B polymorphisms and HBeAg seroconversion or HBsAg clearance. These findings suggest that any association with outcome, if present, is less than that seen in chronic hepatitis C. Additional studies are needed to enlarge sample size and to refine our understanding of IL28B biology in the context of chronic hepatitis B response to immunomodulatory and direct antiviral therapy.
在一组95例慢性乙型肝炎患者中，这些患者接受聚乙二醇干扰素和阿德福韦治疗1年，总体上有15%的乙肝表面抗原（HBsAg）丢失，未发现白细胞介素28B（IL28B）基因多态性与e抗原血清学转换或HBsAg清除之间存在关联。这些发现表明，若存在与治疗结果的任何关联，其程度小于在慢性丙型肝炎中所见。需要进一步研究以扩大样本量，并在慢性乙型肝炎对免疫调节和直接抗病毒治疗反应的背景下，完善我们对IL28B生物学特性的理解。
